Advanced search
1 file | 2.07 MB Add to list

Preclinical activity of melflufen (J1) in ovarian cancer

(2016) ONCOTARGET. 7(37). p.59322-59335
Author
Organization
Abstract
Ovarian cancer carries a significant mortality. Since symptoms tend to be minimal, the disease is often diagnosed when peritoneal metastases are already present. The standard of care in advanced ovarian cancer consists of platinum-based chemotherapy combined with cytoreductive surgery. Unfortunately, even after optimal cytoreduction and adjuvant chemotherapy, most patients with stage III disease will develop a recurrence. Intraperitoneal administration of chemotherapy is an alternative treatment for patients with localized disease. The pharmacological and physiochemical properties of melflufen, a peptidase potentiated alkylator, raised the hypothesis that this drug could be useful in ovarian cancer and particularily against peritoneal carcinomatosis. In this study the preclinical effects of melflufen were investigated in different ovarian cancer models. Melflufen was active against ovarian cancer cell lines, primary cultures of patient-derived ovarian cancer cells, and inhibited the growth of subcutaneous A2780 ovarian cancer xenografts alone and when combined with gemcitabine or liposomal doxorubicin when administered intravenously. In addition, an intra- and subperitoneal xenograft model showed activity of intraperitoneal administered melflufen for peritoneal carcinomatosis, with minimal side effects and modest systemic exposure. In conclusion, results from this study support further investigations of melflufen for the treatment of peritoneal carcinomatosis from ovarian cancer, both for intravenous and intraperitoneal administration.
Keywords
intraperitoneal treatment, preclinical, Ovarian cancer, in vivo, melflufen

Downloads

  • Carlier 2016 Oncot 7 37 59322.pdf
    • full text
    • |
    • open access
    • |
    • PDF
    • |
    • 2.07 MB

Citation

Please use this url to cite or link to this publication:

MLA
Carlier, Charlotte et al. “Preclinical Activity of Melflufen (J1) in Ovarian Cancer.” ONCOTARGET 7.37 (2016): 59322–59335. Print.
APA
Carlier, C., Strese, S., Viktorsson, K., Velander, E., Nygren, P., Uustalu, M., Juntti, T., et al. (2016). Preclinical activity of melflufen (J1) in ovarian cancer. ONCOTARGET, 7(37), 59322–59335.
Chicago author-date
Carlier, Charlotte, Sara Strese, Kristina Viktorsson, Ebba Velander, Peter Nygren, Maria Uustalu, Therese Juntti, et al. 2016. “Preclinical Activity of Melflufen (J1) in Ovarian Cancer.” Oncotarget 7 (37): 59322–59335.
Chicago author-date (all authors)
Carlier, Charlotte, Sara Strese, Kristina Viktorsson, Ebba Velander, Peter Nygren, Maria Uustalu, Therese Juntti, Rolf Lewensohn, Rolf Larsson, Jack Spira, Elly De Vlieghere, Wim Ceelen, and Joachim Gullbo. 2016. “Preclinical Activity of Melflufen (J1) in Ovarian Cancer.” Oncotarget 7 (37): 59322–59335.
Vancouver
1.
Carlier C, Strese S, Viktorsson K, Velander E, Nygren P, Uustalu M, et al. Preclinical activity of melflufen (J1) in ovarian cancer. ONCOTARGET. 2016;7(37):59322–35.
IEEE
[1]
C. Carlier et al., “Preclinical activity of melflufen (J1) in ovarian cancer,” ONCOTARGET, vol. 7, no. 37, pp. 59322–59335, 2016.
@article{8047320,
  abstract     = {Ovarian cancer carries a significant mortality. Since symptoms tend to be minimal, the disease is often diagnosed when peritoneal metastases are already present. The standard of care in advanced ovarian cancer consists of platinum-based chemotherapy combined with cytoreductive surgery. Unfortunately, even after optimal cytoreduction and adjuvant chemotherapy, most patients with stage III disease will develop a recurrence. Intraperitoneal administration of chemotherapy is an alternative treatment for patients with localized disease. The pharmacological and physiochemical properties of melflufen, a peptidase potentiated alkylator, raised the hypothesis that this drug could be useful in ovarian cancer and particularily against peritoneal carcinomatosis. In this study the preclinical effects of melflufen were investigated in different ovarian cancer models. Melflufen was active against ovarian cancer cell lines, primary cultures of patient-derived ovarian cancer cells, and inhibited the growth of subcutaneous A2780 ovarian cancer xenografts alone and when combined with gemcitabine or liposomal doxorubicin when administered intravenously. In addition, an intra- and subperitoneal xenograft model showed activity of intraperitoneal administered melflufen for peritoneal carcinomatosis, with minimal side effects and modest systemic exposure. In conclusion, results from this study support further investigations of melflufen for the treatment of peritoneal carcinomatosis from ovarian cancer, both for intravenous and intraperitoneal administration.},
  author       = {Carlier, Charlotte and Strese, Sara and Viktorsson, Kristina and Velander, Ebba and Nygren, Peter and Uustalu, Maria and Juntti, Therese and Lewensohn, Rolf and Larsson, Rolf and Spira, Jack and De Vlieghere, Elly and Ceelen, Wim and Gullbo, Joachim},
  issn         = {1949-2553},
  journal      = {ONCOTARGET},
  keywords     = {intraperitoneal treatment,preclinical,Ovarian cancer,in vivo,melflufen},
  language     = {eng},
  number       = {37},
  pages        = {59322--59335},
  title        = {Preclinical activity of melflufen (J1) in ovarian cancer},
  url          = {http://dx.doi.org/10.18632/oncotarget.11163},
  volume       = {7},
  year         = {2016},
}

Altmetric
View in Altmetric
Web of Science
Times cited: